Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by DJDawgon May 12, 2023 4:24pm
212 Views
Post# 35446250

RE:RE:RE:RE:RE:Question for Eoganacht

RE:RE:RE:RE:RE:Question for Eoganacht
51% of enrollees end up being responders

Achieving is CR is just the start. Then you have to hold that response.

Ruvidar is achieving 60% of enrollees becoming CR which is better.

Then the quote mentions that "Forty-six percent of responding patients remained in complete response for at least one year". So 46% of 51% is the percent of enrollees that are CR at one year plus.

Maybe we are getting confused by definitions
Enrollees sign up and start on the med
Responders achieve a CR at a point that is usually within a number of months of enrolling
A percent of responders keep being CR

A responder is not always a sustained responded. The may fall off with return of the cancer.

<< Previous
Bullboard Posts
Next >>